The Autosomal Dominant Polycystic Kidney Disease Treatment Market is showcasing a rapidly evolving competitive landscape, with key industry participants such as Bristol-Myers Squibb (US) and Novartis (CH) intensifying their focus on creating innovative therapies. This market is set to grow to USD 3.055 billion by 2035, propelled by a projected CAGR of 5.16%. The increasing prevalence of ADPKD,...